Bprekyba - Company finances
|
EUR
|
2024
From: 2024-06-25
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|
|
Financial data
|
||
| Sales revenue | 27,362 | 18,262 |
| Profit before tax | 4,126 | -3,585 |
| Net profit | 4,126 | -3,585 |
| Equity | 4,126 | 540 |
| Liabilities | 739 | -122 |
| Non-current assets | 0 | 0 |
| Current assets | 4,865 | 418 |
| Total assets | 4,865 | 418 |
|
Financial indicators
|
||
| Revenue change y/y | - | -33.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 84.8% | -857.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 100.0% | -663.9% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 15.1% | -19.6% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 15.1% | -19.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.2 | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Bprekyba - Social security debts
The company had no debts to Sodra
Bprekyba - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Bprekyba, MB (code 306879031) is a Lithuanian small partnership engaged in retail sale of pharmaceutical products. In the latest financial year, 2025, the company generated revenue of €18.3K, down 33.3% year on year from €27.4K in 2024. Net profit turned into a loss of €3.6K in 2025, compared with net profit of €4.1K in the prior year, and the profit margin declined from 15.1% to -19.6%. The two-year pattern therefore shows a clear reversal from profit to loss alongside lower sales. At the end of 2025, total assets were €418, equity €540, and liabilities reported at -€122. The balance sheet is very small, so profitability ratios such as ROE and ROA were strongly negative and should be read in the context of a minimal asset and equity base. Asset turnover was 43.69x in 2025, reflecting revenue generation relative to the limited asset base. No staff data was provided, so revenue per employee cannot be assessed.